QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Puma Biotechnology, Inc. (PBYI)

Healthcare

No action
Fundamental
3
Sentiment
3
Technical
1

Do Nothing: 20-day average dollar volume is $4,500,714, below the $5,000,000 liquidity floor, and the chart is a broken downtrend (price 7.77 below SMA20 9.85 / SMA50 9.75 / SMA200 8.04 and every short average, MACD -0.54 and widening, ADX 26.75 rising on the decline) so technicalScore is 1, under the 3 required; no breakout stop qualifies (there is no base to break — a trigger above the settled 2026-11-13 high 8.12 would be a countertrend bounce in a falling stack) and no pullback/oversold limit qualifies (countertrend limit: price 7.77 < SMA50 9.75 with MACD -0.54 < 0).

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its lead drug, neratinib, targets HER2-positive breast cancer and other solid tumors with HER2 mutations. The company collaborates with Pfizer and several international partners for its drug development and distribution.

Fundamental

fair
Fundamental3
Mixed fundamentals

Puma Biotechnology shows strong cash flow and a solid balance sheet, but faces declining growth and earnings trajectory.

Profitable, debt-free, cash-generative commercial-stage oncology company (neratinib/NERLYNX) at roughly 16.8x trailing earnings, 9.0x EV/EBITDA and an 11.5% trailing free-cash-flow yield, with $108.6M of cash against $4.9M of lease debt and models implying about a double from the current price. Offsetting that: a flat-to-declining single-product top line (five-year revenue CAGR about -2.5%), a collapsing China royalty stream, nine-month 2026 operating income down 55% on a 26% R&D step-up, a disclosed internal-control material weakness, lost patent litigation, permitted US generic entry around 2030, and persistent insider selling. Verdict: mixed - strong balance sheet and cash flow, weak growth and a deteriorating earnings trajectory.

Sentiment

fair
Sentiment3
Neutral sentiment

Sentiment is mildly positive following a Q3 earnings beat, but lacks strong bullish momentum.

Dominant catalyst is the Q3 2026 print (announced, 2026-11-05) — a ~36% non-GAAP EPS beat with FY2026 net income guidance raised, partially offset by a downward product-revenue guidance revision — now ten days old, only partially priced, and with no forward-dated driver inside the next 30 days. The sentiment delta is determinate and mildly positive (~+0.06 baseline → ~+0.20 scoring, both low magnitude), retail is indeterminate on a Reddit access block, and a moderate conflicting-catalyst cap applied because the catalyst array simultaneously carries an in-window bearish director sale; no severe flag fired (zero regulator-confirmed fraud/accounting investigations in 90 days).

Technical

very weak
Technical1
Broken downtrend

The stock is in a confirmed downtrend with price below key moving averages and no tradeable long setup.

Broken downtrend — not a long setup. Price 7.77 sits below every major average: SMA20 9.85, SMA50 9.75, SMA200 8.04, EMA9 8.66, EMA21 9.36, WMA9 8.35, WMA21 9.34 and DEMA14 8.27, and below the 2026-11-13 daily VWAP of 7.93; only TEMA14 at 7.72 is beneath the tape. The sequence is a post-earnings waterfall: 11.50 high on 2026-10-23, 10.69 close into the 2026-11-05 Q3 print, a -9.12% gap to 9.77 on the print, an 8.65/7.59 washout on 2026-11-06, a failed bounce capped at 8.56 across 2026-11-09/11-10, and a fresh closing low of 7.77 on 2026-11-13 (low 7.75). MACD is negative and widening (line -0.54, signal -0.22, histogram -0.32; the line has fallen from -0.19 to -0.54 in four sessions) and ADX14 26.75 is rising off 18.37 on 2026-11-09 while price sits below all averages — that is trend strength pointed down, not up. RSI14 28.11 and Williams %R -94.81 are deeply oversold, but inside a broken stack that is a bounce condition, not a reversal signal. On top of the chart, the 20-day average dollar volume of $4.50M fails the $5M strategy liquidity floor. Chart score 1.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.